CollPlant Biotechnologies Ltd (CLGN)

0.36 +23.45% (+0.07)

Over 5Y: -98.0%

2026-08-28
10 20
2021 2022 2023 2024 2025 2026

Financials Annual

FY21 — Revenue: 15.6M FY21 — Operating Cash Flow: 2.5M FY21 — Free Cash Flow: 1.1M FY21 — Net Income: 237K FY22 — Revenue: 299K FY22 — Operating Cash Flow: -13.7M FY22 — Free Cash Flow: -15M FY22 — Net Income: -16.9M FY23 — Revenue: 11M FY23 — Operating Cash Flow: -2.8M FY23 — Free Cash Flow: -3.7M FY23 — Net Income: -7M FY24 — Revenue: 515K FY24 — Operating Cash Flow: -14.1M FY24 — Free Cash Flow: -14.6M FY24 — Net Income: -16.6M FY25 — Revenue: 2.4M FY25 — Operating Cash Flow: -9.4M FY25 — Free Cash Flow: -9.4M FY25 — Net Income: -11.5M -14M -7M 0 7M 14M 21M
FY21 FY22 FY23 FY24 FY25
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2025-12-31, reported in USD. The newest fact in the filings is dated 2025-12-31, 242 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.6
SBC / sales 42.1%
OE margin -440.6%
Oper. margin -484.3%
ROIC -1851.3%
Accruals -19.2%
Gross margin 64.8%
EBITDA margin -445.8%
FCF margin -398.4%
OCF margin -397.3%
Profit margin -484.6%
ROA -106.5%
ROCE -141.5%
ROE -188.9%
OCF / EBIT —

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.0
RPO / sales —
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

6.0
ND/EBITDA —
Cash runway 0.59 yr
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 2.3×
F-score 3.4 pts
Cash / Debt —
Interest cover —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

5.2
Sales/sh Y/Y +332.1%
Sales CAGR 4Y -37.6%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales Q/Q —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.